Kezar Life Sciences, Inc. Overview
Pro stress-test →Kezar Life Sciences is a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company is developing first-in-class, small molecule therapies designed to inhibit multiple disease-driving cellular pathways by targeting key intracellular proteins.
Strategic Profile
Pro stress-test →The lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). The company is also developing KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics.
Competitive Landscape
Pro stress-test →Kezar competes in the immunoproteasome inhibitor and autoimmune disease treatment space against larger pharmaceutical companies and biotech firms developing competing therapies. Its differentiation lies in first-in-class mechanisms and focused pipeline targeting underserved autoimmune indications.
Industry Context
Kezar Life Sciences, Inc. operates in Biopharmaceuticals - Small Molecule Therapeutics.
Key facts
Founded: 2015 · Headquarters: South San Francisco, California